{"organizations": [], "uuid": "02c240585c5b9e5d9a77c657a9708378978ad539", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-humanwell-healthcare-group-unit-re/brief-humanwell-healthcare-group-unit-receives-fda-approval-idUSL3N1SA1YU", "country": "US", "domain_rank": 408, "title": "Humanwell Healthcare Group unit receives FDA approval", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-03T12:14:00.000+03:00", "replies_count": 0, "uuid": "02c240585c5b9e5d9a77c657a9708378978ad539"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-humanwell-healthcare-group-unit-re/brief-humanwell-healthcare-group-unit-receives-fda-approval-idUSL3N1SA1YU", "ord_in_thread": 0, "title": "Humanwell Healthcare Group unit receives FDA approval", "locations": [], "entities": {"persons": [], "locations": [{"name": "united states", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "llc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "epic pharma", "sentiment": "negative"}, {"name": "humanwell healthcare group", "sentiment": "negative"}, {"name": "humanwell healthcare group co ltd * says co", "sentiment": "negative"}, {"name": "nystatin topical powder", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "u.s food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3(Reuters) - Humanwell Healthcare Group Co Ltd\n* Says coâ€™s wholly owned unit Epic Pharma, LLC received FDA approval for its Nystatin Topical Powder from U.S Food and Drug Administration\n* Says unit will be able to sell this medicine in the United States after receiving the FDA approval\nSource text in Chinese: goo.gl/GKNtvK\n (Beijing Headline News)\nOur ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/GKNtvK", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-03T12:14:00.000+03:00", "crawled": "2018-05-04T16:35:51.006+03:00", "highlightTitle": ""}